|
|
TLR3 |
|
Vaxjo ID |
318 |
|
Vaccine Adjuvant Name |
TLR3 |
|
Description |
Poly(I:C) is an adjuvant that evokes an antitumor response through the Toll-like receptor 3 (TLR3)/TICAM-1 pathway in dendritic cells. It acts on splenic CD8伪(+) DC to cross-prime T cells and on intratumor cells to attract cytotoxic T lymphocytes (CTLs). |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Poly(I:C) has contributed to adjuvant immunotherapy that evokes an antitumor response through the Toll-loke receptor 3 (TLR3)/TICAM-1 pathway in DC |
|
Dosage |
Subcutaneous injection of Poly(I:C) was performed; however, a specific dosage was not provided. |
|
Function |
Collectively, Poly(I:C) tunes up proper maturation of CD8 alpha(+) DC to establish TLR3-mediated IL-12 function and cross-presentation in spleen and lymphocyte-attractive antitumor microenvironment in tumor. |
| References |
Azuma et al., 2016: Azuma M, Takeda Y, Nakajima H, Sugiyama H, Ebihara T, Oshiumi H, Matsumoto M, Seya T. Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology. 2016; 5(8); e1188244. [PubMed: 27622060].
|
|
